Contrarian investing advice from biotech and pharmaceutical stock expert Hartaj Singh, Founding Partner of Tecumseh Partners ...

Zydus Lifesciences is innovating a single-device for semaglutide. This device can deliver multiple strengths of the drug. It ...

An Enquirer analysis found that doctors, nurses and other practitioners received $136 million from pharma and biotech ...

It's been a challenging year for NovoCure (NASDAQ: NVCR), an oncology-focused biotech. NovoCure's average price target on ...

The FDA approved Abbott's Tendyne minimally invasive heart replacement for mitral valve disease that could disqualify ...

Uttar Pradesh's pharma sector attracted ₹2,845 crore investment, creating 70,000+ jobs in three years, aided by the Nivesh ...

The North Carolina Biotechnology Center’s newly relaunched Career Center site is now fully automated. On one recent day, the site listed nearly 2,000 jobs – about 15 times more jobs than the previous ...

The company announced that the USFDA has approved its enhanced PDT system through the agencys Real-Time Review Program. This ...

Orchestra BioMed holds two best-in-class medical device therapies targeting large markets. Find out why OBIO stock is a Buy.

Auxilium’s pivotal trial aims to enrol 80 patients who will receive its NeuroSpan Bridge device for nerve regeneration or a ...

Compumedics has secured a major ~$1 million contract with a leading global pharmaceutical contract research organisation (CRO ...

The pharmaceutical and medical device industries have long utilized speaker programs, which typically involve retaining ...